ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MBRX Moleculin Biotech Inc

5.02
0.01 (0.20%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.01 0.20% 5.02 06:30:00
Open Price Low Price High Price Close Price Previous Close
5.00 4.79 5.2466 5.02 5.01
more quote information »

Recent News

Date Time Source Heading
18/4/202422:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10/4/202422:30PRNUSMoleculin Announces Presentation of Positive Data..
29/3/202401:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
28/3/202400:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
28/3/202400:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25/3/202422:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
23/3/202407:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20/3/202422:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20/3/202422:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
20/3/202407:30PRNUSMoleculin Announces Reverse Stock Split
13/3/202400:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
01/3/202400:30EDGAR2Form 8-K - Current report
23/2/202401:30EDGAR2Form 8-K - Current report
17/2/202409:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/2/202401:15EDGAR2Form 8-K - Current report
15/2/202408:36EDGAR2Form 8-K - Current report
15/2/202408:33EDGAR2Form 8-K - Current report
13/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
03/2/202409:05EDGAR2Form S-1 - General form for registration of securities under..
25/1/202400:50EDGAR2Form 8-K - Current report
25/1/202400:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
17/1/202409:00EDGAR2Form DEF 14A - Other definitive proxy statements
06/1/202409:15EDGAR2Form PRE 14A - Other preliminary proxy statements
06/1/202409:14EDGAR2Form 8-K - Current report
27/12/202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/12/202309:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/12/202309:17EDGAR2Form 8-K - Current report
21/12/202313:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
19/12/202300:55EDGAR2Form 8-K - Current report
12/12/202300:55EDGAR2Form 8-K - Current report
12/12/202300:50EDGAR2Form 8-K - Current report
12/12/202300:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..
21/11/202301:15EDGAR2Form 8-K - Current report
14/11/202300:30EDGAR2Form 8-K - Current report
14/11/202300:05EDGAR2Form 8-K - Current report
14/11/202300:05PRNUSMoleculin Announces Positive Interim Data in Annamycin..
14/11/202300:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202300:00EDGAR2Form 8-K - Current report
14/11/202300:00PRNUSMoleculin Reports Third Quarter 2023 Financial Results
08/11/202300:45EDGAR2Form 8-K - Current report
08/11/202300:45PRNUSMoleculin to Report Third Quarter Financial Results on..
07/11/202300:35EDGAR2Form 8-K - Current report
07/11/202300:35PRNUSMoleculin Presents Positive Preliminary Efficacy Findings..
04/11/202307:30EDGAR2Form 8-K - Current report
18/10/202300:00EDGAR2Form 8-K - Current report
12/10/202300:05PRNUSMoleculin to Participate in the Virtual Investor Ask the CEO..
07/10/202308:15EDGAR2Form 8-K - Current report
02/10/202323:40EDGAR2Form 8-K - Current report
02/10/202323:40PRNUSMoleculin Doses First Subjects in Phase 2 Portion of..
21/9/202322:50EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock